Acetylon Pharmaceuticals Inc., the US-based company, has announced it is starting a Phase 1a/b dose escalation trial of its drug candidate ACY-241 as a monotherapy and in combination with Imnovid® (pomalidomide) and low-dose dexamethasone for relapsed and/or refractory myeloma patients. ACY-241 is a selective inhibitor of the intracellular enzyme histone deacetylase 6 (HDAC6) which works by blocking a specific protein degradation pathway and disrupting critical proliferative signals in myeloma cells. Preclinical data have previously indicated that ACY-241 in combination with pomalidomide synergistically increases myeloma cell death. This will be the first trial in which ACY-241 is being investigated in myeloma.

Read full article